74 results on '"Eom, Ki-Seong"'
Search Results
2. the Prognostic Value of Physical Function in Older Adults with Acute Myeloid Leukemia Treated with Low Intensity Treatment
3. Reduced Toxicity FluBu3 Regimen Showed a Comparable Post-Transplant Outcomes to a Myeloablative BuCy Conditioing in Acute Myeloid Leukemia Patients Receiving First Allogeneic Hematopoietic Stem Cell Transplantation in MRD Negative CR1
4. Impact of Different Donor Types on Post-Transplant Disease Control in Patients with MDS Receiving Anti-Thymocyte Globulin (ATG)-Containing Conditioning
5. Prognostic Value of Genomic Clusters Using Machine Learning in Older Adults with AML
6. Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML
7. Haploidentical Versus Cord Blood Stem Cell Transplantation As the Second Transplant for Relapsed Acute Myeloid Leukemia Patients after the First Stem Cell Transplantation
8. Geriatric Assessment Predicts Non-Fatal Toxicities and Survival for Intensively Treated Elderly Acute Myeloid Leukemia: A Prospective Study
9. Characterization of Philadelphia-Negative Myeloproliferative Neoplasms By the Bone Marrow Immune Microenvironment
10. Superior Survival Outcome of Blinatumomab Compared to Mitoxantrone-Etoposide-Cytarabine Salvage for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Propensity Score-Matched Cohort Analysis
11. Early Bone Marrow Assessment after 7+3 Induction Chemotherapy Is Predictable of Outcome in AML with Adverse Cytogenetics
12. Comparison of Prognostic Impact between the European Leukemia Net (ELN) 2017 Risk Classification and Pre-Transplant WT1 expression in Patients Receiving Allogeneic Transplantation for Acute Myeloid Leukemia (AML)
13. Comparison of Salvage Intensive Chemotherapy Versus Venetoclax Combined Regimen in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
14. A Phase 3 Trial of Thymoglobuline for Prevention of Chronic Gvhd in Transplantation from an HLA-Matched Sibling
15. Effects of Delayed Treatment on Patients with Acute Myeloid Leukemia; Treatment Delay Matters in Younger Patients
16. Physical and Psychological Impairments As Practical Frailty Markers in Elderly AML Fit for Intensive Chemotherapy; Interim Data of a Prospective Cohort Study
17. Natural-Killer Cell Cytotoxicity Is a Diagnostic and Prognostic Marker in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Results from a Prospective Phase II Observational Study
18. Comparison of Myeloablative (CyTBI, BuCy) Versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Low WT1 Expression Level at Transplant
19. Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia
20. Comparable Outcomes between Unrelated Donor (8/8 or 7/8 matched) and Haploidentical Donor for Allogeneic Stem Cell Transplantation in Adult Patients with Severe Aplastic Anemia
21. Genetic Characteristics and Clinical Outcomes of T-Cell Acute Lymphoblastic Leukemia; Myeloid-Suppressive Therapeutic Approach Based on Allogeneic Hematopoietic Cell Transplantation May Benefit in Early T-Cell Precursor Acute Lymphoblastic Leukemia
22. Poor Outcomes of HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation and High Ferritin Levels after a Reduced-Intensity Conditioning Regimen in Patients with Advanced Myelofibrosis
23. Measurable Residual Disease Assay with WT1 Expression in Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation; Optimal Threshold, Time Points, and Candidates
24. Specific Donor Human Leukocyte Antigen (HLA) Allotypes and CMV IgG Serology Status Predict the Risk of Cytomegalovirus-Related Disease in Acute Myeloid Leukemia Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation
25. Natural-Killer Cell Cytotoxicity and Interleukin-2R As a Relevant Marker for Diagnosis of Secondary Hemophagocytic Lymphohistiocytosis in Adult Patients: The Results of Prospective Phase II Observational Study
26. Genetic Characteristics and Long-Term Outcomes of Korean Adult Patients with Ph-like Acute Lymphoblastic Leukemia Versus Non-Ph-like Acute Lymphoblastic Leukemia
27. Progressive Hyperleukocytosis during Initial Therapy Is a Predictive Marker for Differentiation Syndrome and Early Mortality in Adult Patients with Acute Promyelocytic Leukemia
28. Comparable Long-Term Outcomes of Reduced-Intensity and Myeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation By Minimal Residual Disease Kinetics during the Tyrosine Kinase Inhibitor-Based Chemotherapy Courses in Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia in First Remission
29. Low Frequency of CD161+CD4+ T Cells Correlate with the Occurrence of Infections in Refractory/Relapsed Multiple Myeloma Patients Receiving Lenalidomide Plus Low-Dose Dexamethasone Treatment
30. Impact of Chronic Graft-Versus-Host Disease on Long-Term Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia in First Remission
31. Efficacy and Safety of Promace-Cytabom Regimen with Sandwiched Radiotherapy Method in the Treatment of Newly Diagnosed, Stage IE to IIE, Extranodal NK/T-Cell Lymphoma, Nasal Type
32. Long Term Clinical Outcome of Hematopoietic Cell Transplantation for Intermediate to High-Risk Adult AML in Complete Remission; Can We Enhance the Survival Outcome Using Alternative Donor Types?
33. Clinical Manifestations and Treatment Results in Accordance with Frontline Treatment Modalities for Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma (OAML)
34. High Post-Remission WT1 Expression Is a Predictive Marker for Subsequent Molecular Relapse and Poor Survival Outcome in Adult Patients with Acute Promyelocytic Leukemia (APL)
35. Impact of Lenalidomide Plus Low-Dose Dexamethasone Treatment on Immune Cell Populations of the Patients with Refractory/Relapsed Multiple Myeloma
36. Granulocytic and Monocytic Myeloid-Derived Suppressor Cells May Have Different Role on Allogeneic Stem Cell Transplant Outcomes
37. Safety and Efficacy of Iron Chelation with Deferasirox in Adult Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
38. Impact Of CMV Reactivation On Relapse In Patients With Acute Leukemia Who Received Allogeneic Stem Cell Transplantation In First Remission: Possible GVL Effect In CMV Seropositive Population
39. Molecular and Cytogenetic Risk Stratification For Core-Binding Factor-Positive Adult AML With Analysis Of Post-Remission Treatment Outcomes Including Transplantation
40. A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF)
41. Clinical Features of Severe Acquired ADAMTS13 Deficiency in Thrombotic Thrombocytopenic Purpura: Second Report of the Korean TTP Registry.
42. Transplantation From 8/8-Matched or 7/8-Matched Unrelated Donors Compared with HLA-Matched Siblings in Acute Myeloid Leukemia in First Complete Remission
43. Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-Risk MDS and MDS/AML (PODAC).
44. Prognostic Implications of WT1 and BAALC in Adult Patients with Core-Binding Factor Positive or Normal Karyotype AML: Consecutive Analyses From Diagnosis to Hematopoietic Stem Cell Transplantation
45. Graft Source and HLA-Matching Degree-Based Analyses of Long-Term Outcomes of Unrelated Donor Transplants in Adult High-Risk Acute Lymphoblastic Leukemia: Similar Outcomes Between Bone Marrow and Peripheral Blood Progenitor Cells Transplants,
46. Response to Pre-Grafting Hypomethylating Treatment Predicts Transplant Outcomes of MDS
47. The Occurrence of Cytomegalovirus Gastrointestinal Disease in Patients with Gastrointestinal Graft-Versus-Host Disease and Its Related Clinical Outcomes in the Era of Preemptive Therapy for Cytomegalovirus Infection
48. The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia,
49. The Comparison of Allogeneic Stem Cell Transplantation From Family-Mismatched/Haploidentical Donors with Unrelated Donors in Adults with High-Risk Acute Myeloid Leukemia,
50. The Potential Role of Circulating IL-17 Levels During the Peri-Transplant Period as a Predictor for Early Leukemia Relapse After Allogeneic Stem Cell Transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.